摘要
目的对比观察拉米夫定、恩替卡韦在预防和治疗非何杰金淋巴瘤（NHL）合并慢性乙型肝炎病毒（HBV）感染的患者化疗期间出现HBV再激活的有效性。方法2006年6月～2010年6月期间，共收集NHL合并HBV感染患者84例，在化疗同时服用拉米夫定（100rag／d）或恩替卡韦（05mg／d），对病毒学突破率，原发性无应答率、病毒学突破相关性肝炎突发等方面进行对比。结果抗乙肝病毒治疗前HBVDNA〈100copies／mL组，服用拉米夫定或恩替卡韦的病毒学突破率、肝炎突发率无统计学差异（P〉0．05）。抗乙肝病毒治疗前HBVDNA〉10^3copies／mL组，服用托米犬定的患者病毒学突破率为342％，原发耐药率为10．5％，肝炎突发率为26．3％，肝衰竭发牛率为2．6％；服用恩替卡韦的患者上述指标分别为4．2％，0％，0％，0％，两者病毒学突破率及肝炎突发率有统计学差婶（P〈0．05）。结论NHL并HBV感染患者抗乙肝病毒治疗前HBVDNA〈10^3copies／mL，拉米夫定和恩替卡韦疗效相当；抗乙盯病毒治疗前HBVDNA〉10^3copies／mL的患者恩替卡韦有更低的病毒学突破率及肌炎突发率，能史好地保证化疗的顺利进行。
Objective To investigate the efficacy of Lamivudine and Entecavir in preventing and treating HBV reactivation in patients with non - Hodgkin lymphoma （NHL）. Methods Clinical data of 84 NHL patients with HBV infection （from June 2006 to June 2010） were analyzed retrospectively. Each patient took Lamivudine （100 mg/d） or entecavir （0.5 mg/d）. The rate of virological breakthrough, rate of primary non response, rate of chemical - therapy related hepatitis flare were compared in each group. Results Base line HBV DNA〈 103 copies/mL group, Lamivudine and Entecavir showed no significant difference in both virological breakthrough rate and hepatitis flare rate, P 〉0.05. Base line HBV DNA〉 103 copies/mL group, the virological breakthrough rate was 34.2 %, primary non response rate was 10.5 %, the hepatitis flare rate was 26.3 % and the liver failure rate was 2.6 % in Lamivudine - treated group; and the data in Entecavir - treated group were 4.2 %, 0 %, 0 %, 0 %, respectively. Both virological breakthrough rate and hepatitis flare rate showed significant difference, P 〈 0.05. Conclusion The efficacy of Lamivudine and Enteeavir in preventing and treating HBV reactivation in patients with non Hodgkin lymphoma are similar in patients whose base line were HBV DNA〈 103 copies/mL. In patients whose base lines were HBV DNA〉 103 copies/mL, Entecavir can better prevent HBV reactivation.
出处
《实用临床医药杂志》
CAS
2011年第5期21-23,共3页
Journal of Clinical Medicine in Practice
